Z
6ZY
vs
D
DAX Index
Over the past 12 months, 6ZY has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +23% growth.
Stocks Performance
6ZY vs DAX Index
Performance Gap
6ZY vs DAX Index
Performance By Year
6ZY vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zynerba Pharmaceuticals Inc
Glance View
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2015-08-05. Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The firm is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. The company has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).